Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Authors
Keywords
Pancreatic cancer, Chemotherapy, Metastatic, <em class=EmphasisTypeItalic >nab</em>-paclitaxel, Gemcitabine, FOLFIRINOX
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-04-03
DOI
10.1007/s10637-018-0598-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis
- (2017) AnaFernández Montes et al. Journal of Cancer Research and Therapeutics
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014
- (2017) Kyu-Won Jung et al. Cancer Research and Treatment
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
- (2016) Ferdinando De Vita et al. BMC CANCER
- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
- (2016) E Gabriela Chiorean et al. BRITISH JOURNAL OF CANCER
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
- (2016) Stacey M Stein et al. BRITISH JOURNAL OF CANCER
- FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
- (2016) SJ Rombouts et al. Journal of Cancer
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
- (2015) J. Tabernero et al. ONCOLOGIST
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy
- (2012) Todd M. Bauer et al. CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modelling prognostic factors in advanced pancreatic cancer
- (2008) D D Stocken et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now